Fludarabine, cyclophosphamide, and rituximab (FCR) plus GM-CSF as frontline treatment for patients with Chronic Lymphocytic Leukemia

FCR, the standard of care for frontline treatment of CLL patients, is associated with a high rate of neutropenia and infectious complications. GM-CSF reduces myelosuppression and can potentiate rituximab activity. We conducted a clinical trial combining GM-CSF with FCR for frontline treatment of 60...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Leuk Lymphoma
Glavni autori: Strati, Paolo, Ferrajoli, Alessandra, Lerner, Susan, O’Brien, Susan, Wierda, William, Keating, Michael J, Faderl, Stefan
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4487862/
https://ncbi.nlm.nih.gov/pubmed/23808813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.819574
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items